Allarity Therapeutics, Inc. ALLR 深 沪
等待开盘 08-19 09:30:00 美东时间
0.9101
-0.048
-5.00%
华盛通- 最 高0.958
- 今 开0.93
- 成交量 74.23万股
- 最 低 0.84
- 昨 收 0.958
- 总市值 1372.39万
- 52周最高 5.94
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6138
- 委 比 79.25%
- 总股本 1507.96万
- 历史最高 15288000.00
- 量 比 3.45
- 振 幅 12.32%
- 历史最低 0.6138
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stoc...
08-18 15:15
Allarity Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 28.57 percent. This is a 95.51 percent increase over losses of $(3.34) per share
08-16 04:32
Allarity Therapeutics Delays 10-Q Filing
Allarity Therapeutics ( ($ALLR) ) has released a notification of late filing. A...
08-15 06:28
Ascendiant Capital Initiates Coverage On Allarity Therapeutics with Buy Rating, Announces Price Target of $9
Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announces Price Target of $9.
07-28 17:39
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
Allarity Therapeutics has signed a commercial agreement with a EU-based biotech company, granting a global license to its DRP® algorithms for breast cancer and laboratory services. The partnership supports precision oncology solutions and secures lab service commitments. CEO Thomas Jensen highlighted DRP's broad applicability and the lab's expertise. DRP uses gene expression profiling to predict tumor responses, potentially improving patient outc...
07-15 12:00
Jeffrey S. Ervin Appointed as Allarity’s New CFO
An announcement from Allarity Therapeutics ( ($ALLR) ) is now available. On Jun...
07-07 20:58
Allarity Therapeutics appoints Jeff Ervin as CFO
Allarity Therapeutics (NASDAQ:ALLR) announced on Monday the appointment of Jeff Ervin as the company’s new chief financial officer (CFO). Ervin succeeds Alexander Epshinsky, who will remain engaged w...
07-07 20:08
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
Allarity Therapeutics appointed Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings over 20 years of leadership experience in healthcare and biotech, including roles at DayDayCook and IMAC Holdings. He holds an MBA from Vanderbilt University and currently serves on the board of Cingulate Inc. Ervin's expertise in public company management and financial strategy is expected to support Allarity's clinical dev...
07-07 12:00
Allarity Therapeutics Advances Phase 2 Stenoparib Trial
Allarity Therapeutics ( ($ALLR) ) has provided an announcement. On June 27, 202...
07-01 02:43
Allarity Therapeutics Files Form RW, Has Determined Not To Pursue The Public Offering To Which The Registration Statement Relates; The Registration Statement Has Not Been Declared Effective By The Commission And No Securities Have Been Issued Or Sold Under The Registration Statement.
https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm
06-24 20:18
